Polo-like kinases (Plks) and cancer
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitotic kinases as regulators of cell division and its checkpoints
Nigg, E. A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35048096 · Cited by 1,547
Lane, H. A., & Nigg, E. A. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.6.1701 · Cited by 690
Purification and Molecular Cloning of Plx1, a Cdc25-Regulatory Kinase from Xenopus Egg Extracts
Kumagai, A., & Dunphy, W. G. (1996) · Science · doi:10.1126/science.273.5280.1377 · Cited by 507
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
Liu, X., & Erikson, R. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031523100 · Cited by 472
Polo-like kinase-1 is a target of the DNA damage checkpoint
Smits, V. A. J., Klompmaker, R., Arnaud, L., Rijksen, G., Nigg, E. A., & Medema, R. H. (2000) · Nature Cell Biology · doi:10.1038/35023629 · Cited by 440
Polo-like kinases: a team that plays throughout mitosis
Glover, D. M., Hagan, I. M., & Tavares, Á. A. M. (1998) · Genes & Development · doi:10.1101/gad.12.24.3777 · Cited by 424
polo encodes a protein kinase homolog required for mitosis in Drosophila.
Llamazares, S., Moreira, A., Tavares, A., Girdham, C., Spruce, B. A., Gonzalez, C., Karess, R. E., Glover, D. M., & Sunkel, C. E. (1991) · Genes & Development · doi:10.1101/gad.5.12a.2153 · Cited by 404
Polo-like kinases: positive regulators of cell division from start to finish
Nigg, E. A. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80121-x · Cited by 344
Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., & Strebhardt, K. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1863 · Cited by 327
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
Wolf, G., Elez, R., Doermer, A., Holtrich, U., Ackermann, H., Stutte, H. J., Altmannsberger, H.-M., Rübsamen-Waigmann, H., & Strebhardt, K. (1997) · Oncogene · doi:10.1038/sj.onc.1200862 · Cited by 323
Cited by
Ubiquitin ligases: cell-cycle control and cancer
Nakayama, K. I., & Nakayama, K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1881 · Cited by 1,433
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 653
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jackson, J. R., Patrick, D. R., Dar, M. M., & Huang, P. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2049 · Cited by 473
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., & Adolf, G. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2445 · Cited by 398
Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion
Liu, X., Lei, M., & Erikson, R. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2093-2108.2006 · Cited by 303
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review
Liu, K., Zheng, M., Lu, R., Du, J., Zhao, Q., Li, Z., Li, Y., & Zhang, S. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01304-w · Cited by 287
Inoue, T., Hiratsuka, M., Osaki, M., Yamada, H., Kishimoto, I., Yamaguchi, S., Nakano, S., Katoh, M., Ito, H., & Oshimura, M. (2007) · Oncogene · doi:10.1038/sj.onc.1209857 · Cited by 258
Yissachar, N., Salem, H., Tennenbaum, T., & Motro, B. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.10.069 · Cited by 118
Wu, J., Ivanov, A. I., Fisher, P. B., & Fu, Z. (2016) · eLife · doi:10.7554/elife.10734 · Cited by 117
“PLK1 deregulation has been linked with the initiation and progression of many human cancers, including PCa (Cholewa et al., 2013; Takai et al., 2005; Weichert et akl., 2004).”
BackgroundScFv‐Decorated PEG‐PLA‐Based Nanoparticles for Enhanced siRNA Delivery to Her2+ Breast Cancer
Dou, S., Yang, X., Xiong, M., Sun, C., Yao, Y., Zhu, Y., & Wang, J. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400037 · Cited by 39
Therapeutic Targets of KRAS in Colorectal Cancer
Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S. (2021) · Cancers · doi:10.3390/cancers13246233 · Cited by 28
“It has been found to be overexpressed in multiple cancer types including CRC [39].”
BackgroundKaku, Y., Tsuchiya, A., Kanno, T., & Nishizaki, T. (2015) · Pharmacology · doi:10.1159/000381029 · Cited by 20
Metadata
- Authors
- Takai, N., Hamanaka, R., Yoshimatsu, J., & Miyakawa, I.
- Venue
- Oncogene
- Published
- 2005-01-10
- Volume
- 24
- Issue
- 2
- Pages
- 287-291
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2037139254
- Cited by
- 386
- References
- 38
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.